GlassScriptPhysician profile
Katherine E Boggs
NPI 1295170587
$46,260.68
in general payments reported to CMS, 2019-2025
37 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,939 · 2022: $6,151 · 2023: $8,651 · 2024: $13K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,935 · Travel and Lodging: $8,167 · Food and Beverage: $5,533 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,170.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,935.00 |
| Travel and Lodging | $8,167.14 |
| Food and Beverage | $5,533.27 |
| Education | $365.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $19,679.18 | 2023-2025 | Uptravi, Veletri, Opsumit |
| Actelion Pharmaceuticals US, INC. | $17,896.24 | 2021-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $1,485.84 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,172.45 | 2021-2025 | Fasenra, Breztri, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,095.62 | 2021-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $1,004.19 | 2021-2023 | Tyvaso |
| Glaxosmithkline, LLC. | $787.55 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $622.28 | 2021-2025 | |
| Axsome Therapeutics, INC. | $337.82 | 2022-2025 | Sunosi |
| Amgen INC. | $263.07 | 2022-2025 | Tezspire, Tavneos |
| Insmed, INC. | $249.13 | 2024-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $240.16 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $192.23 | 2021-2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $163.93 | 2021-2022 | |
| Harmony Biosciences LLC | $143.74 | 2022-2025 | Wakix |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Genentech USA, INC. | $100.07 | 2021-2024 | Xolair |
| Alexion Pharmaceuticals, INC. | $80.18 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Merck Sharp & Dohme LLC | $76.61 | 2024-2025 | Capvaxive, Winrevair, Recarbrio |
| Vifor Pharma, INC. | $67.13 | 2024-2025 | Zemaira, Veltassa |
| Electromed, INC. | $66.99 | 2021 | |
| Baxter Healthcare | $66.17 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Exeltis, USA INC. | $32.83 | 2022-2024 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $27.12 | 2021 | |
| Optinose US, INC. | $24.71 | 2021 | |
| Axonics, INC. | $21.79 | 2024 | Axonics |
| Viatris Specialty LLC | $20.24 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $19.14 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.52 | 2023 | Acthar |
| Eisai INC. | $17.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.93 | 2022 | |
| Philips North America LLC | $14.91 | 2022 | |
| Grifols USA, LLC | $14.64 | 2021 | |
| Abbvie INC. | $14.33 | 2023 | |
| Hologic Sales and Service, LLC | $13.81 | 2024 | Aptima, Thinprep 2000 Processor |
| La Jolla Pharmaceutical Company | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.